- Home
- CVKD vs RNAZ Comparison
CVKD vs RNAZ Comparison
Compare CVKD & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CVKD | RNAZ |
|---|---|---|
| Founded | 2022 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9M | 8.0M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CVKD | RNAZ |
|---|---|---|
| Price | $5.28 | $8.89 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $13.00 | N/A |
| AVG Volume (30 Days) | ★ 48.7K | 5.2K |
| Earning Date | 05-07-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.94 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.21 | $0.27 |
| 52 Week High | $17.50 | $20.99 |
Technical Indicators
Market Signals| Indicator | CVKD | RNAZ |
|---|---|---|
| Relative Strength Index (RSI) | 48.68 | 49.72 |
| Support Level | $5.13 | $8.29 |
| Resistance Level | $8.87 | $9.44 |
| Average True Range (ATR) | 0.49 | 0.57 |
| MACD | 0.14 | 0.06 |
| Stochastic Oscillator | 64.56 | 41.53 |
Price Performance
Historical ComparisonAbout CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.